title: Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
abstract: OBJECTIVE
  The aim of this study is to confirm the prognostic value of pfetin in gastrointestinal stromal tumor patients. We recently reported the utility of pfetin, a novel prognostic biomarker in gastrointestinal stromal tumor. Gastrointestinal stromal tumor spans a wide spectrum from cases with curable disease to those with fatal tumors due to metastasis and recurrence. There is no biomarker predicting metastasis and/or recurrence of gastrointestinal stromal tumor though imatinib mesylate can improve recurrence-free survival.
  
  
  METHODS
  Pfetin expression was examined in 40 gastrointestinal stromal tumor patients from the Juntendo University Shizuoka Hospital using immunohistochemistry. Correlations between immunohistochemical findings and clinicopathologic parameters were examined. The pfetin expression results were integrated with the clinicopathologic data in a total of 299 cases including our 40 new gastrointestinal stromal tumor cases and 259 others with previously reported data.
  
  
  RESULTS
  Immunohistochemical study demonstrated the disease-free survival rate to be 93.75% for pfetin-positive and 25.0% for pfetin-negative patients among the 40 cases from the Juntendo University Shizuoka Hospital (P= 0.0006). When all 299 cases were included, the disease-free survival rate was 92.44% for pfetin-positive and 60.81% for pfetin-negative patients (P< 0.0001). Both uni- and multivariate analyses revealed that, among the clinicopathologic parameters examined, only pfetin expression was an independent prognostic factor (P< 0.05).
  
  
  CONCLUSIONS
  These results confirm the possible clinical utility of pfetin as a prognostic biomarker for gastrointestinal stromal tumor. Pfetin appears to be a novel clinically applicable prognostic factor, which may be useful for deciding whether to administer imatinib mesylate or not.
authors: Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
authors: Daisuke
authors: D
authors: Kubota
authors: Hajime
authors: H
authors: Orita
authors: Akihiko
authors: A
authors: Yoshida
authors: Masahiro
authors: M
authors: Gotoh
authors: Tatsuo
authors: T
authors: Kanda
authors: Hitoshi
authors: H
authors: Tsuda
authors: Tadashi
authors: T
authors: Hasegawa
authors: Hitoshi
authors: H
authors: Katai
authors: Yasuhiro
authors: Y
authors: Shimada
authors: Kazuo
authors: K
authors: Kaneko
authors: Akira
authors: A
authors: Kawai
authors: Tadashi
authors: T
authors: Kondo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010879:Piperazines / Q000627:therapeutic use; D011506:Proteins / Q000378:metabolism*; D011743:Pyrimidines / Q000627:therapeutic use; D015203:Reproducibility of Results; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; C493175:KCTD12 protein, human; D010879:Piperazines; D011506:Proteins; D011743:Pyrimidines; D000068877:Imatinib Mesylate